glucagon-like peptide 1 receptor agonist(English)

• reduces 3-point major adverse cardiovascular events by 14% in patients with T2D. The benefits of GLP1-RA to reduce ASCVD were at least as large among people with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Also denoted as GLP-1RA
• ASCVD, CKD, CVD, GIP, GLP-1RA, HCC, NAFLD, NASH, SGLT2i, T2DM
• Receptors, Diabetes, Cardiology, Kidney and adrenals
• https://doi.org…jpc.2023.100502
• https://doi.org…000000000001209
• https://doi.org…705190703102816